Show simple item record

dc.contributor.authorGómez Zorita, Saioa
dc.contributor.authorMilton Laskibar, Iñaki
dc.contributor.authorEseberri Barace, Itziar ORCID
dc.contributor.authorBeaumont, Pauline
dc.contributor.authorCourtois, Arnaud
dc.contributor.authorKrisa, Stéphanie
dc.contributor.authorPortillo Baquedano, María Puy ORCID
dc.date.accessioned2023-02-24T15:18:01Z
dc.date.available2023-02-24T15:18:01Z
dc.date.issued2023-02-12
dc.identifier.citationNutrients 15(4) : (2023) // Article ID 928es_ES
dc.identifier.issn2072-6643
dc.identifier.urihttp://hdl.handle.net/10810/60070
dc.description.abstractViniferin is a phenolic compound belonging to the group of stilbenoids. In particular, ε-viniferin is a dimer of resveratrol, found in many plant genders, among which grapes (Vitis vinifera) are a primary source. Due to the fact that ε-viniferin is mainly present in the woody parts of plants, their use as a source of this bioactive compound is a very interesting issue in a circular economy. Both, in vitro studies carried out in pre-adipocytes and mature adipocytes and in vivo studies addressed in mice show that ε-viniferin is able to reduce fat accumulation. Moreover, it prevents the development of some obesity co-morbidities, such as type 2 diabetes, dyslipidemias, hypertension and fatty liver. ε-viniferin can be absorbed orally, but it shows a very low bioavailability. In this scenario, further research on animal models is needed to confirm the effects reported in a great number of studies; to determine which metabolites are involved, including the main one responsible for the biological effects observed and the mechanisms that justify these effects. In a further phase, human studies should be addressed in order to use ε-viniferin as a new tool for obesity management, as a nutraceutical or to be included in functional foods.es_ES
dc.description.sponsorshipThis research was funded by CIBEROBN under Grant CB12/03/30007 and the Government of the Basque Country (IT1482-22).es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectviniferines_ES
dc.subjectobesityes_ES
dc.subjectglucose homeostasises_ES
dc.subjectdyslipidemiaes_ES
dc.subjecthypertensiones_ES
dc.subjectfatty liveres_ES
dc.titleBeneficial Effects of ε-Viniferin on Obesity and Related Health Alterationses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2023-02-24T14:08:56Z
dc.rights.holder© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/2072-6643/15/4/928es_ES
dc.identifier.doi10.3390/nu15040928
dc.departamentoesFarmacia y ciencias de los alimentos
dc.departamentoeuFarmazia eta elikagaien zientziak


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).
Except where otherwise noted, this item's license is described as © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).